Glycomic analysis focused on sulfated O-glycans was performed to identify novel serum carbohydrate tumor markers. Sulfated glycans were enriched by α-neuraminidase digestion of pyridylaminated glycans prepared from sera, followed by anion exchange chromatography. Sulfated O-glycan profiles were constructed by two types of high performance liquid chromatography separation.
Introduction
Carbohydrate antigens are the most frequently used tumor markers. For example, CA19-9 is a serum tumor marker that is often used for the clinical diagnosis of a variety of cancers such as pancreatic, colorectal and stomach cancers and the serum marker CA125 is commonly used to diagnose ovarian cancer (Del Villano et al. 1983; Canney et al. 1984) . CA15-3, DU-PAN-2 (SLe c epitope), STN (Sialyl Tn antigen) and SLX (SLe x epitope) are also useful carbohydrate tumor markers, although these are less frequently used for clinical applications than CA19-9 and CA125 (Chia et al. 1985; Hayes et al. 1986; Kannagi et al. 1986; Takasaki et al. 1988; Motoo et al. 1991) . Recently, serum glycomics and glycoproteomics studies have been extensively performed to identify novel glycan biomarkers for a variety of cancers, primarily using newly developed high-throughput platform technologies, such as mass spectrometrybased methods and lectin-based methods (Okuyama et al. 2006; Kirmiz et al. 2007; Abd Hamid et al. 2008; Jung et al. 2009; Abbott et al. 2010; Alley et al. 2010; Arnold et al. 2011; de Leoz et al. 2011; Adamczyk et al. 2012; Alley et al. 2012; Biskup et al. 2013; Hua et al. 2013; Kaji et al. 2013; Gbormittah et al. 2014; Pan et al. 2014; Hamfjord et al. 2015) .
Our research group has attempted to identify novel carbohydrate tumor markers. The tumor marker oligosaccharide antigens currently in clinical use are thought to be carried on the mucin-type O-glycans (Magnani et al. 1983; Lan et al. 1985; Lloyd et al. 1997 ). Thus, we focused exclusively on O-linked oligosaccharides as the target for the markers.
As an initial step, we analyzed the precise serum O-glycan profiles of healthy controls to generate a database to allow us to search for novel O-glycan tumor marker candidates (Yabu et al. 2014) . Next, we attempted to find glycan markers by means of direct comparison of serum glycan profiles between healthy controls and cancer patients using a high performance liquid chromatography (HPLC)-based method (Tanaka-Okamoto et al. 2016) . Pyridylaminated glycans (PA-glycans) prepared from small numbers of sera samples taken from either normal subjects (10 cases) or cancer patients (15 cases) were separated by two types of HPLC and the fluorescence intensities of the corresponding peaks were precisely compared on the chromatograms. Using this approach, we succeeded in identifying several carbohydrate tumor marker candidates that appeared to be elevated in the sera of cancer patients. One of these candidates had a sialyl Lewis A structure on the core1 framework (abbreviated as C1SLA), and was thought to be a CA19-9 related glycan. Furthermore, a verification study of C1SLA was performed using a selected reaction monitoring (SRM)-based procedure, which revealed that the level of C1SLA was significantly higher in the sera of advanced stage gastric cancer and pancreatic cancer patients compared to normal controls. Thus, we reasoned that C1SLA could be a valuable diagnostic adjunct for cancer (Tanaka-Okamoto et al. 2016 ). These results indicated that the HPLC-based procedure used in our study was an effective means of identifying novel glycan marker candidates. Verification studies of the other candidates identified in the previous study using the SRM method are currently underway. We have subsequently searched for glycan marker candidates using a modified method, termed focused glycomics, as detailed below.
Among the carbohydrate antigens currently in clinical use, the structures of CA19-9, DU-PAN-2, STN and SLX are, at least partially, analyzed. CA19-9, DU-PAN-2, STN and SLX are all NeuAc (neuraminic acid)-linked acidic glycans as are the marker candidates identified in our previous study, such as C1SLA. Indeed, NeuAclinked glycans are major components of human tissues and sera (Yabu et al. 2014) .
However, non-NeuAc linked acidic glycans, mainly composed of sulfated glycans, are also expressed in human cancer tissues. We reported the presence of colon cancers that express a variety of sulfated glycosphingolipids, such as 6-sulfo Lewis X, 6′-sialyl 6-sulfo lactosamine and 3′-sialyl 6-sulfo Lewis X, as the major components ). Moreover, immunohistochemical analyses revealed the presence of sulfate containing oligosaccharides in cancerous tissues, such as colorectal and gastric cancers (Izawa et al. 2000; Okayama et al. 2011) . Furthermore, structural analyses revealed that sulfated O-glycans are major components in human cancer tissues, such as colon cancers and pancreatic cancers (unpublished results of our laboratory) and ovarian cancer ascites (Karlsson and McGuckin, 2012) . These results strongly suggested that special attention needs to be paid to sulfated oligosaccharides as marker candidates. Thus, in this study, we have attempted to identify marker candidates by focusing on sulfated oligosaccharides as targets.
NeuAc-linked acidic O-glycans and neutral O-glycans account for approximately 95 and 5% of total O-glycans in human sera, respectively (Yabu et al. 2014) . Similarly, NeuAc-linked acidic N-glycans and neutral N-glycans account for around 83 and 17% of total N-glycans, respectively (Natsuka et al. 2014) . Thus, sulfated glycans comprise only a very minor component of sera. Consequently, many peaks derived from major glycans, NeuAc-linked acidic and neutral glycans, are observed on the HPLC chromatogram. However, peaks derived from sulfated glycans were predicted to be either very minor or undetectable. Therefore, minor sulfated marker candidate peaks are easily overlooked due to the overlapping peaks derived from abundant glycans. In order to resolve this problem and exhaustively identify as many candidate peaks as possible, an enrichment process for sulfated glycans is required. This enrichment procedure involves removing nontarget NeuAc-linked acidic and neutral glycans in PA-glycan mixtures before assembling the glycan profiles.
Thus, a simple sample preparation was introduced to enrich for sulfated PA-glycans, which involved neuraminidase digestion of PAglycan mixtures, followed by anion exchange chromatography prior to two different types of HPLC separation. Serum PA-glycan mixtures were digested with α-neuraminidase from Arthrobacter ureafaciens, which releases NeuAc regardless of its linkage position (α2-3, α2-6 and α2-8). Upon digestion, NeuAc-linked acidic oligosaccharides are transformed to neutral oligosaccharides. However, this is not the case for oligosaccharides that are neuraminidase resistant acidic glycans, such as sulfated glycans. When these neuraminidase treated PA-glycan mixtures are subjected to weak anion exchange chromatography, neutral glycans and NeuAc-linked acidic oligosaccharides, which comprise the vast majority of serum glycans, elute at the position corresponding to neutral glycans (Figure 1) . Crucially, however, sulfated oligosaccharides elute in the acidic fraction, regardless of whether the sample has undergone neuraminidase digestion. Consequently, sulfated glycans are enriched in the acidic fraction.
In this study, serum sulfated O-glycan profiles from 20 healthy controls and 20 adenocarcinoma patients with gastric (11 cases) and pancreatic cancers (9 cases) were compared. Our analysis facilitated the identification of 14 sulfated carbohydrate tumor marker candidates. The fine structures of 14 candidates were precisely elucidated. Furthermore, the levels of these sulfated candidates in sera from all 40 individuals were quantified using SRM analyses and their potential for clinical application was evaluated.
Results
Enrichment of sulfated PA-glycans in PA glycan mixtures prepared from human sera Serum PA-glycan mixtures from 20 healthy controls, 11 gastric cancer patients (G1-G11), and 9 pancreatic cancer patients (P1-P9) were prepared (Table I) . The clinical information of 20 cancer patients are summarized in Table I . In order to identify novel markers it is preferable to use sera from advanced stage cancer patients. Thus, with the exception of one early stage pancreatic cancer patient, P9, all the other patients were at an advanced stage (III/IV). Note that serum from P9 was included with the aim of identifying marker candidates of early pancreatic cancer. Among the 20 cancer patients, 15 cases showed high values of CA19-9 and/or CEA. Sera of five cases, G1, G4, G5, G11 and P9, showed normal ranges of both markers.
A 40 µL sample of PA-glycan mixture (equivalent to mixtures derived from 20 µL of serum) was used for the focused glycomics analysis. In our previous study, PA-glycan mixtures prepared from human sera were subjected to two different types of HPLC separation without any treatment. In this study, to enrich for sulfated oligosaccharides, PA-glycan mixtures were digested with α-neuraminidase from Arthrobacter ureafaciens prior to separation according to acidity by weak anion exchange chromatography (Figure 1 ). Figure 1 , line A NA(−) shows the elution profile for DEAE anion exchange chromatography of PA-glycan mixtures prepared from human sera without neuraminidase digestion. Arrowheads labeled N and A1-A4 indicate elution positions of standard neutral PA-glycans and standard PA-glycans with 1-4 neuraminic acids (NeuAc), respectively. A single peak was observed in the neutral position and six peaks in the acidic fractions between A1 and A4. This analysis suggested that the acidic glycans, composed primarily of NeuAc-linked glycans, were more abundant than neutral glycans. Figure 1 , line B NA(+) shows the elution profile of DEAE anion exchange chromatography of PA-glycan mixtures digested with neuraminidase. By contrast to undigested PA-glycans, almost all the neuraminidase digested glycans eluted at the neutral position. Indeed, only one major peak was observed in the neutral fraction, composed of the original neutral glycans and NeuAc-linked glycans that were neutralized after digestion. A very minor peak was observed in the A1 fraction (indicated by an asterisk), corresponding to unlabeled NeuAc liberated by neuraminidase. Minor peaks could also be observed in the A2-A4 acidic fractions when the chromatogram was enlarged. All the acidic fractions from A1 to A4 areas were collected, which include sulfated glycans and artifacts as major components. In addition to sulfated glycans, it is possible that glycans containing deaminoneuraminic acid (KDN), an unusual sialic acid in human, are included as very minor components in this acidic fraction. During the course of this study, we found that candidate glycans eluted after the A1 fraction. In order to examine these findings in more detail, the acidic fraction in the A1 area and A2-A4 areas were also separately collected and then subjected to the same analyses.
Comparison between serum sulfated PA-O-glycan profiles of normal controls and those of adenocarcinoma patients
Fractions containing the sulfated glycans from DEAE ion exchange chromatography were separated by normal phase HPLC (Figure 2 ). PA-glycans that eluted up to 50 min were found to be O-linked glycans and those that eluted after 50 min were primarily N-linked glycans, as judged by MS analyses. (The elution pattern of serum sulfated PA-O-glycans and sulfated PA-N-glycans in normal phase HPLC is shown in Supplemental Figure S1 .) HPLC chromatograms obtained from healthy controls and cancer patients were compared to identify marker candidate peaks. These candidate peaks were defined as either: (i) peaks present in samples from cancer patients but absent from those derived from the healthy controls or (ii) peaks found in samples from cancer patients that are significantly elevated compared to the corresponding peaks from normal controls.
Using these criteria, we were able to detect candidate peaks on normal phase HPLC and/or following reversed phase HPLC in the samples from three gastric cancer patients (G3, G7 and G10) and four pancreatic cancer patients (P2, P3, P4, P8) (see HPLC chromatograms in Figures 2 and 3). However, no such peaks were identified in the samples from the other 13 cancer patients included in this study. Representative HPLC chromatograms of three normal controls (N) are also shown in Figures 2 and 3 . In the sample from P4, four markedly elevated peaks (N1, N2, N3 and N4) were observed. Whereas elevated peaks N2, N3 and N4 were only found in the sample from P4, elevated levels of peak N1 were also observed in samples from G3, G10, P2 and P8 (Figure 2 ). Peaks with an elution time of approximately 15 min, which appear to be increased in samples from cancer patients, were found to be artifacts (i.e., no PA-glycans as judged by MS analysis). There are three peaks at around 23.5, 25 and 28 min (Fraction 3) commonly observed in samples from normal controls and cancer patients. Structural analyses revealed the following: (i) second peak (elution time at around 25 min) was composed of core2 glycan sulfated at the 6-position of GlcNAc (Galβ1-4(HSO 3 -6)GlcNAcβ1-6 (Galβ1-3)GalNAc) and (ii) first and third peaks (elution time at around 23.5 and 28 min, respectively) were composed mainly of artifacts, but not PA-glycans.
Even when the normal phase chromatograms were enlarged, no candidate peaks other than N1-N4 could be detected. In the following results section, all the candidates were numbered according to their glycan structures. N1, N2, N3 and N4 were numbered Nos. 10, 12, 13 and 14, as shown in the parenthesis.
Sulfated O-linked oligosaccharides eluting between 10 and 55 min in normal phase HPLC were divided into seven fractions (Fr1-Fr7) and each fraction was collected. Candidate peak N1 was from Fraction 4, N2 and N3 from Fraction 5 and N4 from Fraction 6. Each of the fractions were further separated by reversed phase HPLC (Figure 3) , and the HPLC chromatograms obtained from healthy controls and cancer patients were then compared in detail (Figure 3 ). This process enabled the identification of a variety of candidate peaks.
In all, we were able to identify a total of 14 candidate peaks; 2, 1, 1, 3, 4 and 3 peaks from Fractions 1, 2, 3, 4, 5 and 6, respectively (indicated by dotted lines in Figure 3 , Table II ). No candidate peaks were found in Fraction 7. These candidates were numbered (i.e., Nos. 1-14) according to the O-glycan basal structure (core1 and core2) as described in the next section. Representative examples of reversed phase chromatograms (full-scale) of Fractions 4 and 5 are shown in Figure 3A and C, respectively (left-hand side in Figure 3 ). The corresponding magnified views of Fractions 4 and 5 are shown in Figure 3B and D, respectively (right-hand side in Figure 3 ). In Fraction 4, No. 10 (N1) and No. 11 were observable in the fullscale chromatogram, whereas another candidate, No. 5 could only be detected in the corresponding magnified view ( Figure 3A and B). Similarly, in Fraction 5, No. 12 (N2) and No. 13 (N3) were observed in the full-scale chromatogram, and the two other candidates, Nos. 6 and 7 could only be seen in the magnified view of the chromatogram ( Figure 3B and D). The asterisked peaks shown in Figure 3A -D were judged to be artifacts because MS/MS analyses revealed that these compounds were not composed of general glycan components such as hexose and HexNAc.
Structural analyses of candidate glycans by mass spectrometry
These candidate peaks were further analyzed by mass spectrometry. MS 2 analyses revealed that all of the 14 candidates were monosulfated glycans (Table II) . This finding confirmed that the enrichment process for sulfated glycans had been successful. Among these 14 candidates, 11 were also mono- (7 candidates , under the conditions used in this study. Mass data, estimated composition and estimated structures of candidate sulfated glycans are presented in Table II . A sulfate group (HSO 3 ) and phosphate group (H 2 PO 3 ) have very similar mass values. Nonetheless, we concluded that all the candidates were sulfated glycans for the following reasons. Firstly, sulfated, but not phosphorylated, PA-glycans are ionized as TEA adducted protonated ions under the conditions used in this study. Secondly, the sulfate group, but not phosphate group, is released by methanolysis. Most of the candidate glycans were methanolyzed and the release of the sulfate groups was confirmed.
Linkage positions of fucose and sulfate could not be determined under the MS/MS conditions used in this study (Harvey et al. 2002; Kenny et al. 2011) . Furthermore, in core1 glycans having more than five oligosaccharide backbone structures, it was not possible to differentiate whether the core structures of these glycans were composed of straight or branched chain oligosaccharides (Table II, Nos. 5-9). Nonetheless, the overall structures of Hex and HexNAc could be estimated from the data.
The number of candidate PA-glycans having core1 and core2 structures were 9 (Nos. 1-9) and 5 (Nos. 10-14), respectively. In addition, several isomers were included in the core1 and core2 PAglycans.
For (Table II) . All the core1 glycans, except one, No. 4, were peeling products lacking GalNAc at the reducing terminal end (Table II) . We previously reported that O-glycans having extended core1 structures (longer than four glycans) are highly susceptible to base catalyzed β-elimination (peeling), and most of them lack a reducing terminal GalNAc (Tanaka-Okamoto et al. 2016) . Because No. 4 PA-glycan is composed of three glycans, the reducing end terminal GalNAc remains intact.
In the core2 glycans, the presence of a Hex-Hex-HexNAc sequence in the terminal β1-6 branch was demonstrated by careful examination of product ions in the MS 2 spectra of Nos. 13 and 14.
Our results suggested that these two glycans have histo-blood group B antigen.
Precise structural analyses of candidate glycans
The structures of these sulfated glycans were precisely analyzed using a combination of two-dimensional mapping, enzymatic digestion and mass spectrometry together with methanolysis and synthesis of sulfated oligosaccharides using glycosyltransferases as performed in our previous study ). We had already obtained standard PA-O-glycans, which included type1 and type2 core1 basal structures, Galβ1-3GlcNAcβ1-3Gal and Galβ1-4GlcNAcβ1-3Gal, respectively, and core2 structure Galβ1-4GlcNAcβ1-6(NeuAc α2-3Galβ1-3)GalNAc. These reference compounds were used to identify the structures of the candidates. The quantities of the sulfated glycans obtained from sera samples was too small for the precise analyses. Thus, in addition to the patient sera samples, we used various samples including cancer, adenoma, normal tissues from stomach, pancreas and colon, together with the supernatant of colorectal cancer cell lines, SW1116, as a source of sulfated candidate glycans. The amount of candidate glycans varied between samples. PA-O-glycans showing the same chromatographic behavior and mass as Nos. 1 and 2 were present in most of the samples analyzed. Sufficient quantities of sulfated glycans of Nos. 3, 5, 6 and 8 were found in pancreatic mucinous adenoma tissue for our structural analyses. Similarly, sulfated glycans of Nos. 7 and 9 were found in the supernatant of SW1116 cells. Moreover, No. 10 glycan was relatively abundant in some of the colorectal cancer tissues.
Accordingly, the structures of all 14 candidates were estimated and are given in Table III . The series of analytical approaches employed in these structural analyses are illustrated in Figure 4A -E. Our previous experiments revealed that methanolysis (abbreviated as M in Figure 4 ) under the conditions used in this study hydrolyzes about 90% of the sulfate linked galactose or GlcNAc residues, and 75% of fucosyl residues. Therefore, when sulfofucosylated oligosaccharide was treated by methanolysis, desulfated-defucosylated backbone structures appeared as the main peak. In the following results section, the structures of these PA-oligosaccharides are explained in detail. All the reacted products, such as enzymatic digestion and methanolysis, were subjected to mass spectrometry.
Core1 glycans: Nos. 1 and 2 were methanolyzed and the products appeared at the position of type1 core1 standard Galβ1-3GlcNAcβ1-3Gal, but not type2 core1 standard Galβ1-4GlcNAcβ1-3Gal on the map ( Figure 4A ). Digestion of monofucosylated No. 2 with α1,3/4-fucosidase (abbreviated as 3/4F) resulted in conversion to No. 1. No. 1 was resistant to Jack bean β-galactosidase, which is capable of cleaving galactose linked β1-3 or β1-4 to GlcNAc, but not galactose when sulfate is linked at the C3 position. Thus, we suspected No. 1 to be HSO 3 -3Galβ1-3GlcNAcβ1-3Gal. In order to confirm this speculation, 3′ sulfated Galβ1-3GlcNAcβ1-3Gal was synthesized by sulfation of Galβ1-3GlcNAcβ1-3Gal using COS 7 cell lysate transfected with human β-Gal-3-O-sulfotransferase 2 (Gal3ST-2, GP3ST) expression vector, pcXN2-GP3ST (abbreviated by 3′ST). As anticipated, No. 1 was identical to HSO 3 -3Galβ1-3GlcNAcβ1-3 Gal. Thus, Nos. 1 and 2 were estimated to have a 3′-sulfo type1 lactosamine and 3′-sulfo Lewis A structure, respectively (Table III) .
Methanolized product of No. 3, (i.e., backbone structure of No. 3) was identical to type2 core1 standard Galβ1-4GlcNAcβ1-3Gal, but not Continued 406 M Tanaka-Okamoto et al.
type1 core1 standard Galβ1-3GlcNAcβ1-3Gal on the map ( Figure 4B ). No. 3 was digested with α1,3/4-fucosidase. It has been reported that Jack bean β-galactosidase (abbreviated as G) can hydrolyze Galβ1-4(HSO 3 -6)GlcNAc, whereas β1-4 galactosidase from Streptococcus pneumoniae cannot hydrolyze the linkage. After defucosylation, No. 3 could be digested with Jack bean β-galactosidase, and the digestion product contained a sulfate group, indicating that sulfate is linked to the GlcNAc residue but not the terminal galactose. No. 3 was predicted to possess a 6-sulfo Lewis X structure. Our findings suggest that the sulfate in the No. 4 candidate is linked at the C6 position of the terminal GlcNAc (Table III) . Backbone composition of Nos. 5, 6, 7, 8 and 9 was Hex 3 HexNAc 2 -PA ( Figure 4C and D) . It is noteworthy that all these glycans possess a characteristic structure, type1 and type2 lactosamine hybrid structure. Among them, No. 6 is composed of a straight chain oligosaccharide ( Figure 4C ), while the other four glycans, No. 5, 7, 8 and 9, comprise branched chain oligosaccharides ( Figure 4D ), as detailed below.
Methanolyzed product of No. 6 was judged to be a straight chain, Hex-HexNAc-Hex-HexNAc-Hex-PA, because the product bion at m/z 731 corresponding to [Hex-HexNAc-Hex-HexNAc+H] + was clearly observed in the MS 2 spectrum. After sequential digestion of methanolyzed product with β1,4-galactosidase (abbreviated as 4G) and human placental β-N-acetylhexosaminidase (abbreviated as Hex), the digestion product ran on the 2D map at the same position as reference compound Galβ1-3GlcNAcβ1-3Gal, indicating that the backbone structure of No. 6 was a type1-type2 lactosamine hybrid, Galβ1-4GlcNAcβ1-3Galβ1-3GlcNAcβ1-3Gal ( Figure 4C ). Moreover, No. 6 could be cleaved by α1,3/4-fucosidase. Under the conditions used in this study, α1,3/4-fucosidase can cleave the fucosyl residue linked to a subterminal GlcNAc, but not an internal GlcNAc. This enzyme specificity indicated that the fucose residue is linked to a subterminal GlcNAc. Defucosylated product was digested with Jack bean β-galactosidase. Digestion of the agalacto form with human placental β-N-acetylhexosaminidase, which is able to cleave terminal HSO 3 -6GlcNAc residues, released a HexNAc-HSO 3 residue, as measured by mass spectrometry, indicating that the sulfate is linked to a subterminal GlcNAc. From these results, the structure of No. 6 is predicted to have a 6-sulfo Lewis X structure at the nonreducing terminus as shown in Table III . Nos. 5, 7, 8 and 9 have the same branched backbone structure, type1 and type2 lactosamine linked to the C3 and C6 position of galactose, respectively, Galβ1-4GlcNAcβ1-6(Galβ1-3GlcNAcβ1-3) Gal, as evidenced below ( Figure 4D ). Methanolyzed products of these candidates were cleaved by Jack bean β-galactosidase, and two galactose residues were released. Lacto-N-biosidase (abbreviated as B) digestion of the backbone released one type1 lactosamine unit. Although the lacto-N-biosidase digestion product was different from the type2 standard, Galβ1-4GlcNAcβ1-3Gal, it could be sequentially digested with β1,4-galactosidase and β-N-acetylhexosaminidase, suggesting that the type2 lactosamine unit was linked to the C6 position of galactose, Galβ1-4GlcNAcβ1-6Gal. Furthermore, linkage of a type1 lactosamine unit to the C3 position of galactose was also confirmed by the following structural analyses.
Digestion of No. 8 with α1,3/4-fucosidase released two fucosyl residues, indicating that the fucoses were linked to both type1 and No. 14 type2 lactosamine. The product of the digest coincided with the position of No. 5 on the map. Defucosylated product (No. 5) could be sequentially digested with lacto-N-biosidase and Jack bean β-galactosidase. The digested product was 6-sulfo GlcNAcβ1-6Gal. These results indicated that Nos. 5 and 8 comprises a 6-sulfo type2 lactosamine and 6-sulfo Lewis X structure on the β1-6 arm, respectively.
After sequential digestion with β1,4-galactosidase and β-Nacetylhexosaminidase, the digestion products of No. 7 ran on the 2D map at the same position as No. 2. Similarly, after sequential digestion with α1,3/4-fucosidase β1,4-galactosidase and β-N-acetylhexosaminidase, the digestion products of No. 9 ran on the 2D map at the same position as No. 1. These results indicated that both Nos. 7 and 9 have a 3′sulfo Lewis A structure on the β1-3 arm. . Strategy used to estimate the precise structure of sulfated candidate PA-O-glycans. The candidate glycans were isolated from human cancer, adenoma, normal tissues, supernatant of a cancer cell line and sera from patients. The structures of these candidates were determined by employing a combination of methods, including sequential enzymatic digestion, methanolysis, mass spectrometry and synthesis of sulfated oligosaccharides using glycosyltransferases. Enzyme and glycosyltransferase abbreviations are: 3/4 F; α1,3/4-fucosidase, G; β-galactosidase from Jack bean, Hex; β-N-acetylhexosaminidase from human placenta, 4G; β1,4-galactosidase from Streptococcus pneumoniae B; lacto-N-biosidase, S; α2,3-sialidase, αG; α-galactosidase from green coffee bean, 3′ST; sulfation to C3 position of galactose by β-Gal-3-O-sulfotransferase 2. M indicates methanolysis. Symbol representation of glycans are: Galactose β1-3 linked to GlcNAc (type1), closed circle; galactose β1-4 linked to GlcNAc (type2) and β1-3 linked to GalNAc, open circle; galactose α1-3 linked to galactose, gray circle; GlcNAc, open square; GalNAc, closed square; fucose, open triangle; S, sulfate.
Core2 glycans: Five different core2 candidates were found to be highly elevated in the sera of P4 (Figure 2 ). Sialylated forms of these candidates were isolated from the PAglycan mixture prepared from P4 sera. We concluded that sialic acid is linked to the terminal galactose residue on the β1-3 arm because the product ion at m/z 753, corresponding to [NeuAc-HexHexNAc-PA+H] + , was observed in the MS 2 spectra of these oligosaccharides (data not shown). These results indicated that fucose and sulfate were linked to the type2 lactosamine unit on the β1-6 arm. Because No. 12 is monosulfated and difucosylated, it is highly likely that No.12 possesses a 6-sulfo Lewis Y structure on the β1-6 arm. Similarly, we suspected Nos. 10 and 11 have either a 6-sulfo Lewis X or 6-sulfo type2H structure. To analyze the precise structure of these candidates, monosialylated, monosulfated and monofucosylated O-glycan, which is likely to be one of the core2 candidate O-glycans, was isolated from cancerous colon tissues. Methanolysis, sequential enzymatic digestion, and mass spectrometry revealed that the structure of this glycan was Galβ1-4(Fucα1-3)(HSO 3 -6) GlcNAcβ1-6(NeuAcα2-3Galβ1-3)GalNAc, having a 6-sulfo Lewis X structure on the β1-6 arm ( Figure 4E ). Digestion of this glycan with α2-3 sialydase (abbreviated as S) resulted in conversion to No. 10. No. 12, isolated from P4 sera, was digested with α1,3/4-fucosidase. The resulting digestion product was identical to No. 11 on the map. Nos. 10, 11 and 12 were predicted to possess 6-sulfo Lewis X, 6-sulfo type2H and 6-sulfo Lewis Y structures, respectively (Table III) . Nos. 13 and 14 were speculated to have histo-blood group B antigen by MS/MS analyses. Both Nos. 13 and 14 could be digested with α-galactosidase from green coffee bean (abbreviated as αG), and the digestion products were identical to Nos. 11 and 12, respectively ( Figure 4E ).
Quantification of levels of sulfated marker candidate PA-glycans in sera of healthy controls and adenocarcinoma patients by SRM
We identified 14 marker candidates in the differential analyses of enriched sulfated PA-O-glycans prepared from healthy controls and cancer patients, based on the chromatogram of fluorescence detection. Among the 14 candidates, some of the corresponding peaks were very minor. Precise quantification of the levels of these candidates is required to confirm whether their elevation is real. Furthermore, precise quantification of the levels of these candidates will also facilitate preliminarily evaluation of the usefulness of each candidate. However, precise levels of these candidates from the 40 cases cannot be determined by simply measuring the fluorescence peak areas of the chromatograms due to the low level of sensitivity and accuracy, as easily seen in the reversed phase chromatograms (Figure 3) . Therefore, levels of these candidate glycans were quantified using an SRM assay as performed in our previous study. Specifically, fractions containing candidate PA-glycans in the reversed phase HPLC were collected, and subjected to SRM analyses. The SRM method displays a high degree of sensitivity for the quantification of sulfated candidate glycans. However, in this experiment high accuracy could not be fully guaranteed because we were unable to prepare internal standards that are required for precise quantification. Nonetheless, this semi-quantitative evaluation of the levels of the various glycans provided interesting information with regard to the properties of each candidate. Furthermore, this SRM quantification was performed twice, and very similar results were obtained from both analyses.
To examine the performance of our SRM assay, we constructed standard curves of four kinds of sulfated candidates, Nos. 1, 3, 6 and 9, in order to assess the linear range (Supplemental Figure S2) . Sulfated PA-glycans at nine different concentrations ranging from 0.03 to 300 fmol were subjected to SRM analyses in triplicate for each sample. These analyses revealed that, similar to non-sulfated PA-glycans, a linear correlation between the peak areas and quantities of analyzed sulfated PA-glycans was obtained over three orders of magnitude, spanning from 0.1 to 300 fmol, measured in the experiment (R 2 > 0.99). Furthermore, although four candidates had a wide range of Q1 values, from lowest 805.4 (No. 1) to highest 1462.7 (No. 9), similar ionization efficiencies were observed. Based on the observation of signal-to-noise ratio of extracted ion chromatograms (XIC) corresponding to transitions monitored for candidate PA-glycans, we used an intensity of 500 as the limit of quantification (LOQ).
The calculated mass of [M+TEA+H]
+ was used for the Q1 transition (Table II) . Two selected Q3 transitions monitored for the candidate PA-glycans are listed in Table II . The more abundant transition of the two was selected as the quantifier transition to be used in quantitative analyses. The peak area in the chromatogram of each SRM transition was then measured. Each level of candidate marker determined by the SRM assay in sera taken from 11 gastric cancer patients, 9 pancreatic cancer patients and 10 normal controls is shown in Figure 5A -N. (Because very similar results were obtained from 20 normal controls, representative SRM data from only 10 out of the 20 cases are shown.) The values estimated to be LOQ were plotted to 0. In order to compare the level of each individual candidate marker, the levels were plotted as separate bar graphs rather than a scatter plot. Because very high values, 2-3 orders of magnitude higher than normal controls, were observed in samples from cancer patients of three core2 candidates, Nos. 12, 13 and 14, the levels of these candidates were expressed on a logarithmic 10 (log(10)) scale ( Figure 5L, M and N) . The levels of the other candidates were expressed on a linear scale.
Elevation of all the candidate glycans in samples of at least one or more cancer patients was observed. The levels of each candidate in the sera of cancer patients showed various patterns. However, several characteristic features were observed in candidate markers with the same core structure.
In nine core1 glycans (Nos. 1-9, Figure 5A -I), candidates having a short backbone of less than four oligosaccharides, Nos. 1, 2, 3 and 4 ( Figure 5A-D) are elevated in a few cancer cases, even though they include glycans having a characteristic structure such as 6-sulfo Lewis X (No. 3) and 3′-sulfo Lewis A (No. 2). By contrast, the other five kinds of core1 candidates, possessing a characteristic structure, type1-type2 lactosamine hybrid backbone with 6-sulfo Lewis X (Nos. 6 and 8), 3′-sulfo Lewis A (Nos. 7 and 9) and 6-sulfo lactosamine structures (No. 5), are elevated in a significant proportion of sera derived from both gastric and pancreatic cancer patients ( Figure 5E-I) . For example, the levels of No. 5 in the sera of four cases of gastric and seven cases of pancreatic cancer were greatly increased compared to those of normal controls ( Figure 5E ). The levels of Nos. 6 and 9 of all the 20 normal controls were under LOQ, while the levels of these candidates of more than 10 cases of cancer patients out of 20 greatly exceeded LOQ ( Figure 5F and I) . Furthermore, the levels of these core1 candidate markers varied widely between patients. Nos. 6 and 8 have the same glycan determinant, 6-sulfo Lewis X, on the terminus of the straight chain and branched β1-6 arm, respectively. The level of No. 6 is greatly increased in sera of P3 and G3 ( Figure 5F ). However, for candidate No. 8, extremely high levels were found in P8 as well as G9, P4 and P3 ( Figure 5H ). Candidates Nos. 7 and 9 have very similar glycan structures, each possessing a 3′-sulfo Lewis A determinant on a branched β1-3 arm. The level of No. 7 was much increased in sera of G3 and P3, while the level of No. 9 increased vastly in sera of G7 and G9 ( Figure 5G and I) . Furthermore, a remarkable increase of No. 5, which is a nonfucosylated form of No. 8, was found in sera of G10 in addition to P3 and P4 ( Figure 5E ). Taken together, our results strongly indicate that multiple analysis of these candidates, rather than employing a single candidate marker, will form the basis of a robust detection system for a wide range of cancer patients.
In core2 glycans (Nos. 10-14, Figure 5J-N) , No. 10 has a 6-sulfo Lewis X structure without α1-2 fucosylation, and the other four candidates, Nos. 11, 12, 13 and 14, have a fucose residue α1-2 linked to galactose. Both Nos. 13 and 14 have histo-blood group B antigen. In agreement with the results of these structural analyses, Nos. 13 and 14 could be quantified in sera of cases of AB or B blood type without exception. The levels of No. 13 could be quantified in sera of four, three, and four cases of gastric cancer patients, pancreatic cancer patients and normal controls, respectively ( Figure 5M ). These 11 cases are AB or B blood group (Table I ). The levels of No. 13 in the other 19 cases, who are A or O blood group, are LOQ. The value of No. 14 could be quantified in 2 cases of blood type B.
Four candidates, Nos. 10, 12, 13 and 14, which were detected by first normal phase HPLC as peaks N1, N2, N3 and N4, respectively, were all core2 glycans. Unlike core1 candidates, elevation of these core2 candidates was observed mainly in sera of 1 or 2 specific patients, P2 and P4. For example, elevation of No. 11 was observed in only one case, P4 ( Figure 5K ). Highest and second highest values of the other four candidates, Nos. 10, 12, 13 and 14, were found in sera of P4 and P2, respectively (Figure 5J, L, M and N) . In particular, these five values of P4 were an order of magnitude higher than any of the other cases.
Although the number of analyzed cases is small, comparison of these sulfated candidates with conventional markers, CA19-9 and CEA, suggested that these candidates could at least serve as an adjunct to the conventional markers. For example, sera from G7 and G10 exhibited a slight increase of CA19-9 and a normal range of CEA (Table I) . However, the level of Nos. 2 and 9 in G7 was greatly elevated. Similarly, the level of No. 5 in G10 was around one order of magnitude greater than those of 20 normal cases.
In addition to ABO blood group antigen, Lewis blood group type (Le) and secretor status (Se) related carbohydrate antigens were included among the candidates-the former are Nos. 2, 7 and 9, having Lewis A structure, and the latter are Nos. 11, 12, 13 and 14, having a fucose residue α1-2 linked to a galactose. It should be emphasized that elevation in the levels of these candidates is not derived from any bias of blood group sampling between cancer patients and normal controls. Among the 40 cases, 39 cases (20 adenocarcinoma and 19 normal controls) were judged to be Lewis positive individuals because measurable values of CA19-9 can be determined. One of the normal controls might be Lewis negative because CA19-9 was consistently found to be below the detection limit. Information regarding the Se status of each case was not available. Nonetheless, the value for No. 11 was elevated in only 1 case of pancreatic cancer, P4, whereas the other cancer patients and 20 normal controls show similar values.
Discussion
In our previous study, a carbohydrate tumor marker candidate was identified by comparing total O-glycan profiles of patients and healthy subjects using a HPLC-based method, and then further verification was performed by utilizing a SRM-based procedure (Tanaka-Okamoto et al. 2016) . In this study, we focused on sulfated O-glycans as potential tumor marker candidates. To carry out this focused glycomics approach effectively, sulfated O-glycans were enriched by removing large amounts of nontarget glycans, NeuAclinked acidic and neutral glycans. This enrichment was achieved by performing a neuraminidase digestion of PA-glycan mixtures followed by DEAE anion exchange chromatography. Sulfated PA-Oglycans prepared from sera taken from either normal subjects or cancer patients were separated by two types of HPLC and the fluorescence intensities of the corresponding peaks were precisely compared on the chromatograms. This approach enabled us to identify 14 sulfated carbohydrate tumor marker candidates that appeared to be elevated in the sera of cancer patients. Similar results were obtained using samples digested with α-neuraminidase from Salmonella typhimurium. Some researchers have reported performing serum glycome analyses to identify markers with specific oligosaccharide structures using lectins (Okuyama et al. 2006; Jung et al. 2009; Kaji et al. 2013) . However, this is the first study to focus on sulfated glycans as potential marker candidates.
Although cleavage of NeuAc by neuraminidase digestion was very effective for this focused glycomics approach, alteration of the original structure of the oligosaccharide was unavoidable. Sulfated candidate glycans detected in this analysis corresponded to nonNeuAc linked and NeuAc linked sulfated glycans. Thus, using this approach the original structure of candidate glycans elevated in the sera cannot be determined.
In this study, O-glycans were released from serum proteins by hydrazine treatment at 60°C for 16 h. However, under these conditions, large amounts of peeling product (35-42% to total O-glycans) were observed (Yabu et al. 2014; Tanaka-Okamoto et al. 2016) . Thus, it is essential to reduce the peeling process in order to obtain more reliable results. Several studies that greatly reduced the peeling reaction have been reported (Miura et al. 2010; Kozak et al. 2012) . In future, optical methods to reduce the peeling products are highly required.
Quantification of the candidate glycans in sera from 40 individuals (20 cancer patients and 20 normal controls) by SRM furnished preliminary but valuable information concerning the availability of each candidate for clinical applications. Moreover, this information could not be obtained by HPLC fluorescence detection and quantification alone.
An elevation in specific serum carbohydrate species are associated with certain cancers, which include 3′-sulfo Lewis A, 6-sulfo Lewis X, and type1 and type2 lactosamine hybrid structures. Although the number of analyzed samples are small, core1 glycans having type1 and type2 lactosamine hybrid structures with 6-sulfo Lewis X (Nos. 6 and 8), 6-sulfo lactosamine (No. 5) or 3′-sulfo Lewis A structures (Nos. 7 and 9) seem to be reliable markers. Moreover, core2 glycans appear to be elevated in the sera of particular cancer patients. Among the five core2 candidates analyzed in this study, No. 21, having a 6-sulfo Lewis X structure, seems to be a more promising candidate than the other four core2 candidates having a α1-2 fucosylated structure. Because most of the candidates have sulfofucosylated determinants, concomitant sulfation and fucosylation appears to be an important characteristic of tumor marker glycans. Indeed, the findings of our previous study, which examined the serum O-glycans profiles of normal controls, led to a similar conclusion (Yabu et al. 2014) . Core2 glycans having only 6-sulfation on the GlcNAc residue without fucosylation Galβ1-4 (HSO 3 -6)GlcNAcβ1-6(NeuAcα2-3Galβ1-3)GalNAc are present at around 0.02-0.05% of total O-glycans. In this study, the corresponding desialylated product, Galβ1-4(HSO 3 -6)GlcNAcβ1-6 (Galβ1-3)GalNAc was commonly observed in samples from both normal controls and cancer patients (Figure 2 , second peak of Fraction 3). However, the 3-fucosylated form, Galβ1-4(HSO 3 -6) (Fucα1-3)GlcNAcβ1-6(Galβ1-3)GalNAc (i.e., No. 10 candidate) appears to be elevated in samples from cancer patients.
Elevation of GlcNAc6-O-sulfotransferase and Gal 3-O-sulfotransferase activities were found in human gastric cancer tissues compared with adjacent normal tissues (Chandrasekaran et al. 2007 ). Similar results were obtained in human pancreatic cancers . Levels of 14 sulfated marker candidate glycans in sera from gastric cancer patients, pancreatic cancer patients, and normal controls. The peak area in the extracted ion chromatogram (XIC) of each SRM transition was measured. (A-N) The levels of 14 candidate glycans, Nos. 1-14, respectively, in sera from 11 gastric cancer patients (G1-G11), 9 pancreatic cancer patients (P1-P9) and 10 normal controls (N). The levels of candidate marker from the sera of gastric cancer patients (G), pancreatic cancer patients (P), and normal controls (N) are indicated by a gray bar, black bar and white bar, respectively. Due to space constraints, only odd numbered cases are shown in each figure. The levels of three candidates, Nos. 12, 13 and 14 , were expressed on a logarithmic 10 (log(10)) scale ( Figure 5 L, M, N) . The levels of the other candidates were expressed on a linear scale. The mass values (Q1 mass), estimated structure, and candidate number (Nos. 1-14), which were all shown in Table II and Figure 4 , are presented in each graph.
(unpublished results in our laboratory). Increase of transcription levels of GlcNAc6ST-2 in human gastric cancers compared with paired normal mucosa has also been reported (Okayama et al. 2011) . Thus, one possible mechanism underlying the alteration of O-glycan profiles is upregulation of GlcNAc6-O-sulfotransferases and Gal 3-O-sulfotransferase activities in human gastric and pancreatic cancers.
For core1 glycans, candidates having type1 and type2 lactosamine hybrid structures (Nos. 5-9) seem to be more promising cancer markers than short glycans having only type1 or type2 structures. We previously reported the unusual accumulation of sulfofucosylated glycosphingolipids having type1 and type2 lactosamine straight chain hybrid structures in colon cancer ). Such species are structurally similar to No. 6 found in this study. However, these hybrid structures have never been detected in normal colon tissues. In addition to the straight chains, there have been some articles reporting the presence of O-glycans having branched type1 and type2 hybrid structures (Mutsaers et al. 1986) .
Among the candidates identified in this study, some are elevated in the sera of a variety of gastric and pancreatic cancer patients, while others are increased in only one or two cancer cases. In particular, the former group of candidates appear to be useful markers for the diagnosis of gastric and pancreatic cancers. This information is very important for understanding the properties of each candidate marker. However, we cannot exclude the possibility that even those candidates evaluated to be of low potential as biomarkers for gastric and pancreatic cancers in this study, might be suitable for other forms of cancer such as ovarian cancers. Furthermore, the observed increase in the level of candidate marker varied on a case by case basis. Analysis of multiple markers will inevitably increase the reliability of the assay. Indeed, our results indicate that it is highly desirable to comprehensively evaluate a wide variety of candidate markers, if possible, all the candidates, for the subsequent verification studies.
We will aim to utilize this SRM assay, especially using stable isotope-labeled glycan as internal standard, for the following verification study. This assay was established in our previous study and has been demonstrated to exhibit at least equivalent sensitivity and specificity to that of an immunoassay. As such, the assay is sufficiently sensitive to quantify the sulfated candidate glycans. In addition, the method is a suitable platform for multiplexing. Currently, at least five candidates can be quantified in a single assay, even when two SRM channels are used. Further optimization of this assay is anticipated to facilitate the quantification of much greater numbers of candidates per assay run. This multiplexing format will be extremely valuable for the subsequent verification studies of the multiple candidate markers. 
LC-SRM/MS
All samples were analyzed using nano-LC-SRM/MS on a 4500 Q Trap hybrid triple quadrupole/linear ion trap mass spectrometer (Applied Biosystems, Framingham, MA) equipped with a nanoESI device (AMR, Inc., Tokyo, Japan) connected to a Paradigm MS4 µHPLC system (Michrom BioResources Inc., Auburn, CA). Reversed phase HPLC was performed at room temperature on a Magic C18 column (5 µm, 0.2 × 50 mm; Michrom BioResources) with a FortisTip capillary needle (AMR, Inc.) at a flow rate of 2 µL/min. The solvents used were (A) 5 mM acetic acid titrated to pH 6.0 with triethylamine and (B) 50% (v/v) acetonitrile. The column was pre-equilibrated with solvent A, and 3 min after injection of sample, solvent B was increased to 100% over 1 min and then held at 100% for 10 min. Data acquisition was performed with an ion spray voltage of 2200 V, curtain gas of 20 psi, nebulizer gas of 15 psi, an interface heater temperature of 150°C and dwell time of 50 ms. Two collision energies of 40 and 50 V or 50 and 60 V, declustering potential of 140 V, and collision cell exit potential of 15 V, were used for all SRM transitions. Two SRM transitions were monitored and acquired at low resolution both in the first and third quadrupoles (Q1 and Q3). SRM data acquired on the 4500 QTRAP were analyzed by MultiQuant v2.1.1 (Applied Biosystems). Integration settings included a smoothing width of one point and a peak splitting factor of 2. The more abundant transition of the two transitions was selected as the quantifier transition to be used in quantitative analyses. The peak area in the XIC of each SRM transition was measured.
Supplementary data
Supplementary data are available at Glycobiology online.
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